Retinal Pigment Epithelium and Microglia Transplantation in Age-related Macular Degeneration.
Early trials suggest transplanting retinal cells could restore vision in age-related macular degeneration, moving cell therapy toward clinical reality.
This review in the American Journal of Ophthalmology synthesizes current evidence on retinal pigment epithelium (RPE) and microglia transplantation as a cell-based therapy for age-related macular degeneration, a leading cause of irreversible blindness. The authors discuss clinical translation challenges and highlight emerging trials demonstrating early feasibility, positioning AMD cell therapy at the frontier of vision restoration approaches.
What the study was
- Study design
- Narrative review
- Population
- Patients with age-related macular degeneration (AMD), primarily advanced/geographic atrophy or neovascular AMD
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- American Journal of Ophthalmology
Why it surfaced
Novel cell therapy approach (RPE + microglia co-transplantation) for AMD, a condition affecting millions with limited treatment options; Am J Ophthalmology review with emerging clinical trial data.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.